Indications:
KEYTRUDA is indicated for the first-line treatment of patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
KEYTRUDA is indicated for the treatment of adult and pediatric patients aged 3 years and above, with relapsed or refractory classical Hodgkin lymphoma (cHL), who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumours express PDL1 (CPS ≥10) as determined by a validated test and who have not received prior chemotherapy for metastatic disease (see clinical studies).
*Evaluated as part of Project Orbis
|